Jupiter Asset Management Ltd. maintained its position in Pfizer, Inc. (NYSE:PFE) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 705,137 shares of the biopharmaceutical company’s stock at the end of the first quarter. Pfizer accounts for about 0.9% of Jupiter Asset Management Ltd.’s holdings, making the stock its 25th largest position. Jupiter Asset Management Ltd.’s holdings in Pfizer were worth $24,123,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Norges Bank purchased a new position in Pfizer during the fourth quarter valued at approximately $1,896,890,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Pfizer during the fourth quarter valued at about $289,666,000. Appaloosa LP bought a new stake in shares of Pfizer during the fourth quarter valued at about $156,229,000. I.G. Investment Management LTD. boosted its stake in shares of Pfizer by 24.7% in the fourth quarter. I.G. Investment Management LTD. now owns 11,087,884 shares of the biopharmaceutical company’s stock valued at $360,134,000 after buying an additional 2,194,738 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Pfizer by 8.2% in the fourth quarter. Macquarie Group Ltd. now owns 24,455,341 shares of the biopharmaceutical company’s stock valued at $794,310,000 after buying an additional 1,845,343 shares during the last quarter. 69.94% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer, Inc. (PFE) opened at 32.67 on Friday. The stock’s 50 day moving average price is $33.30 and its 200 day moving average price is $33.38. The firm has a market cap of $194.30 billion, a price-to-earnings ratio of 23.90 and a beta of 1.00. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.38.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm posted $0.64 earnings per share. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.92%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.
COPYRIGHT VIOLATION NOTICE: “Pfizer, Inc. (PFE) Position Held by Jupiter Asset Management Ltd.” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/19/jupiter-asset-management-ltd-has-24123000-stake-in-pfizer-inc-pfe-updated.html.
Several analysts have issued reports on PFE shares. Sanford C. Bernstein restated a “buy” rating and issued a $35.00 target price on shares of Pfizer in a report on Monday, April 24th. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price target on shares of Pfizer in a report on Thursday, April 27th. Barclays PLC reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Finally, ValuEngine cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $37.61.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
About Pfizer
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
